Navigation Links
Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S.,Phase I REOLYSIN Trial

(MTD), dose limiting toxicity (DLT), and safety profile of REOLYSIN(R) when administered systemically to patients. A secondary objective is to examine any evidence of anti-tumour activity. Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the results of the Phase I US Systemic Administration clinical trial investigating delivery of REOLYSIN(R) for advanced cancers, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, actual patient tolerance, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory
'"/>




Page: 1 2 3

Related medicine technology :

1. Oncolytics Biotech Inc.s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:8/1/2014)... PALO ALTO, Calif. , Aug. 1, 2014 ... today announced a partnership to expand awareness of proper ... the CFChef Shares program. CFChef Shares will run from ... AbbVie,s CFChef program – an online resource for CF ... a healthy diet by submitting recipes to the ...
(Date:8/1/2014)... Mass. , Aug. 1, 2014  NxStage Medical, Inc. ... dialysis products, today announced that Jeffrey H. Burbank , ... Officer, will present at the 34 th Annual Canaccord ... Boston, MA , on Wednesday, August 13 th ... will be made available at http://ir.nxstage.com/ .  ...
(Date:8/1/2014)... Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced ... report its second quarter 2014 financial results on Monday, ... J. Joseph Kim and CFO Peter ... corporate update, and participate in a live Q&A with ... VGX-3100, Inovio,s immune therapy targeting pre-cancers and cancers associated ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
(Date:8/1/2014)... Gerontological Society of America (GSA) ... field of aging has chosen Madonna Harrington ... PhD, of the University of Luxembourg; and Philipp ... The London School of Economics and Political Science ... Innovative Publication Awards. , These distinguished honors recognize ...
(Date:8/1/2014)... 2014 Lifeinsurancenomedicalexam.info has released a ... for clients who have high cholesterol levels. , ... and qualify for no medical exam life insurance. These ... background medical check-ups. , Since there are no medical ... will qualify in just a few minutes. However, this ...
(Date:8/1/2014)... August 01, 2014 Home Care Assistance ... seniors, is honored to be recognized as a 2014 Best ... given to home care providers who rank in the top ... on monthly satisfaction interviews conducted by Home Care Pulse. , ... home care businesses, the best of the best!” says Home ...
(Date:8/1/2014)... aesthetic injectable procedures have grown in popularity as more ... As Botulinum toxin generally known as BOTOX ... health professionals have emerged to perform procedures utilizing this ... Spinelli, MD from the Division of Plastic Surgery Presbyterian ... from Columbia University in New York have assessed the ...
(Date:8/1/2014)... CapsCanada, a leading provider of ... new K-CAPS® (HPMC capsules) manufacturing facility in Lakeshore, ... last year while experiencing growing global demand for ... “KCAPS® are currently sold in more than 60 ... to other HPMC capsules, K-CAPS® have exceptional appearance ...
Breaking Medicine News(10 mins):Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2Health News:Cincinnati Senior Care Company Receives 2014 Best of Home Care® Employer of Choice Award 2Health News:Plastic surgeons or nurses: Who are the better injectors? 2
... focused on the use of cholesterol-lowering drugs also ... and C-reactive protein levels. C-reactive protein is a ... inflammation in the arteries. One study shows C-reactive ... cardiovascular risk.,Researchers focused on whether the lower low-density ...
... heart's own can, such as raising the heart rate when ... hill but researchers say a pacemaker created by // stem ... shown that genetically engineered heart cells from human embryonic stem ... to a new study. Researchers injected clusters of human beating ...
... body’s immune system and help protect the body against ... shows promising treatment for acute myelogenous leukemia // ... from a patient’s family member. Researchers say this ... cancer of the bone marrow that has become resistant ...
... unexpected structural differences in the brains of cocaine addicts. ... brain structure // of 27 cocaine addicts to that ... ,Results showed the amygdala -- a key structure in ... brain's reward processing system -- is smaller in cocaine ...
... more important factor associated with childhood allergies and asthma than ... to a new study . // ,The study ... a sample of their cord blood serum taken at birth ... showing a sensitization to certain allergens.The children were assessed at ...
... Epilepsy is a disorder caused by abnormal surges in the ... is found to affect more than 2 million people worldwide. ... by just taking medications. // ,Researchers now say that ... effective surgery is compared to drug therapy when treating those ...
Cached Medicine News:
The AIA-600 II has become the new standard in benchtop immunoassay analyzers....
... The ACON PSA Semi-Quantitative Prostate Specific ... Blood/Serum/Plasma) are lateral flow tests in strip ... of Prostate Specific Antigen (PSA). The tests ... ng/mL cut-off values, and all come with ...
... Assess Functional Vision, Quality of Vision ... controls both target illumination and glare ... testing results. Day/Night testing with/without glare ... Standards and all ANSI standards. All ...
... is Recognized as a Valuable Tool ... by Early Eye Disease. Near Test ... 7 in (12.7cm x 17.78cm) Can ... Refractor,Distance Test F.A.C.T. 201: Size ...
Medicine Products: